

Eli Lilly introduces Ramiven for certain high-risk early breast cancer patients in India

24 November 2022 | News

Abemaciclib is a CDK4/6 inhibitor which has now been approved for HR+ HER2 - node positive high risk earlybreast cancer

Eli Lilly and Company (India) has announced the launch of the additional indication for Ramiven (abemaciclib), following approval from The Drug Controller General of India (DCGI) in combination with endocrine therapy for adjuvant treatment in adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, nodepositive early breast cancer (EBC) at high risk of recurrence.

CDK 4/6 inhibitors are a class of medicines used to treat certain types of metastatic breast cancers. In India, over 50,000 patients are diagnosed with HR+/HER2- early breast cancer (EBC) every year. Close to 30% of EBC patients with high-risk clinical or pathological features experience recurrence or metastasis despite receiving standard therapy.

Vineet Gupta, Managing Director, Eli Lilly and Company - India & India Subcontinent, said, "Breast cancer is the cancer which is most prevalent amongst women in India. It significantly impacts the quality of life of survivors and their families, who live with the fear of recurrence. The approval of Ramiven for treatment of Early Breast Cancer brings more optimism by providing a new treatment option to the healthcare professionals for their patients."

Ramiven is already approved for the treatment of certain types of HR+ HER2- advanced or metastatic breast cancer.